26/10/2017 : Revenues at the end of September 30, 2017

Revenues to September 30, 2017: +7%Continuing strong growth in theranostics sales: +27%Percentage of revenues from internal products maintained: 74%Croissy-Beaubourg and Montpellier, October 26, 2017, 6:00pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specializing…

Continue Reading26/10/2017 : Revenues at the end of September 30, 2017

16/10/2017 : Eighth test in Theradiag’s monitoring range launched in the USA

Croissy-Beaubourg and Montpellier, October 16, 2017, 8:00am CET – THERADIAG (ISIN: FR0004197747, ticker: ALTER, eligible for PEA-PME equity savings plans in France), a company specializing in in vitro diagnostics and theranostics, today announces that its…

Continue Reading16/10/2017 : Eighth test in Theradiag’s monitoring range launched in the USA

30/06/2017 : Further strong sales growth in the first half of 2017: +9%

Excellent momentum for theranostics sales: +43%Second-quarter revenue growth: +12%  Croissy-Beaubourg and Montpellier, July 25, 2017, 6 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specializing in in vitro diagnostics and theranostics,…

Continue Reading30/06/2017 : Further strong sales growth in the first half of 2017: +9%